Related Experiment Video

Updated: Aug 9, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma

Antonella Tacconelli1, Antonietta R Farina, Lucia Cappabianca

  • 1University of L'Aquila, Department of Experimental Medicine, Via Vetoio, Coppito 2, 67100 L'Aquila, Italy.

Future Oncology (London, England)
|March 25, 2006
PubMed

Insights

The tyrosine kinase receptor (Trk)-A was thought to suppress tumors in neuroblastoma. However, a new TrkAIII variant promotes tumor growth, suggesting alternative splicing is key to neuroblastoma behavior.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pediatric Cancer Research

Background:

  • The tumor-suppressor role of tyrosine kinase receptor (Trk)-A in neuroblastoma was established based on its association with better prognosis and inhibition of tumor growth.
  • This established concept is challenged by the discovery of a novel, hypoxia-regulated TrkAIII splice variant predominantly expressed in advanced-stage neuroblastoma.

Purpose of the Study:

  • To review and integrate novel findings on the TrkAIII splice variant.
  • To propose a modified concept of TrkA's role in neuroblastoma, considering alternative splicing.
  • To identify TrkAIII as a potential prognostic biomarker and therapeutic target.

Main Methods:

  • Review of existing literature on TrkA expression, function, and splice variants in neuroblastoma.
  • Integration of data on the novel TrkAIII splice variant, including its regulation, expression patterns, and functional effects.
  • Analysis of TrkAIII's impact on neuroblastoma phenotype, including angiogenesis and stress resistance.

Main Results:

  • The TrkAIII splice variant exhibits tumor-promoting activity in neuroblastoma xenografts.
  • TrkAIII induces a more angiogenic and stress-resistant neuroblastoma phenotype.
  • TrkAIII antagonizes the anti-oncogenic signaling of nerve growth factor/TrkAI.

Conclusions:

  • Alternative TrkA splicing is a potential pivotal regulator of neuroblastoma behavior.
  • The TrkAIII splice variant may serve as a prognostic biomarker for neuroblastoma patients.
  • TrkAIII represents a potential novel therapeutic target for neuroblastoma treatment.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...